Takeda, Regeneron, Sanofi and BMS trim pipelines in Q2 updates; BMS drops Ph3 prostate cancer degrader BMS-986365, Takeda cuts celiac drug TAK-101.
Biopharma earnings season is also pipeline update season.
On Wednesday, Takeda, Regeneron, Sanofi and Bristol Myers Squibb all announced program cuts as part of their …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…
Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept…
AstraZeneca posts Q2 pipeline setbacks: mixed ADC data in gastric cancer, an Ultomiris TMA trial miss and an Imfinzi liver cancer…
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance…
Biogen pauses or cancels most R&D programs from its $5.6B Apellis buyout and lays off staff, keeping its focus on Empaveli and…
By Moitreyee Chatterjee-Kishore, Ph.D., MBA, Head of Oncology Development, Astellas Pharma Inc. | How targeted protein degraders…
